. Author manuscript; available in PMC: 2020 Jun 10.

Published in final edited form as: Am J Kidney Dis. 2018 Feb 27;71(6):851–865. doi: 10.1053/j.ajkd.2017.12.009

Table 3.

Summary of Randomized Clinical Trials in the Field of Serum Urate and Cardiovascular Diseases

CV field	Intervention	Primary Outcomes	ID No. and Status
BP control	Febuxostat vs allopurinol	Clinic BP and ABPM	NCT01701622^a; terminated (unable to enroll participants)
Coronary endothelial dysfunction	Febuxostat vs placebo	Coronary flow	NCT01763996^a; completed
BP control	Febuxostat vs placebo	ABPM	NCT01496469^a; completed
Exercise tolerance in chronic angina	Febuxostat vs placebo	ETT	NCT01549977^a; terminated
Vascular structure and function (FORWARD)	Febuxostat vs allopurinol	Carotid-femoral PWV	EudraCT 2014–5567-33; enrollment closed
New-onset metabolic syndrome (FAST)	Febuxostat vs placebo	Insulin resistance and features of metabolic syndrome	NCT01654276^a; ongoing
BP and CV complications (CARES)	Febuxostat vs allopurinol	MACE	NCT01101035^a; ongoing
Treatment of CHD (ALL-HEARTY)	Allopurionl vs placebo	MACE	EudraCT 2013–003559-39; Ongoing
Cerebrovascular protection (XILO-FIST)	Allopurinol vs placebo	White matter protection	NCT02122718^a; starting Recruitment
Major CV diseases (FREED)	Febuxostat vs placebo	MACE	NCT01984749^a; ongoing

Abbreviations: ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CHD, coronary heart disease; CV, cardiovascular; ETT, exercise tolerance testing; MACE, major adverse cardiovascular events; PWV, pulse wave velocity.

ClinicalTrials.gov.